Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

November 2007, Regeneron Pharmaceuticals ($REGN @Regneron) entered into a global, strategic collaboration with Sanofi ($SNY @Sanofi) to discover, develop, and commercialize fully human monoclonal antibodies (the “Antibody Collaboration”). The Antibody Collaboration is governed by the companies’ Discovery and Preclinical Development Agreement (“Antibody Discovery Agreement”) and a License and Collaboration Agreement. Upfront Payment $85MM for Regeneron […]

Synovex (Boston, MA), a clinical stage biotechnology company focused on inhibiting the progression of fibrotic diseases such as arthritis, closed a $3.5M Series C financing. Participants were not identified.

Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.

MabVax Therapeutics (San Diego, CA), a clinical-stage biotechnology company focused on cancer immunotherapies, closed a $5.3M Series B financing. Participants include Numoda Capital Innovations, Burrill & Co. and RTP Venture Fund. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive […]

Alethia Biotherapeutics (Canada), a preclinical-stage biotechnology company focused on bone degredation, closed a $4.7M Series B financing. Participants include AgeChem Venture Fund, BDC Venture Capital and GO Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account […]

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

BerGenBio (Norway) a preclinical-stage biopharma company focused on receptor tyrosine kinase inhibition for the treatment of cancer, closed a $8.8M Series A financing. Participants include Sarsia Seed and Investinor.

Arteaus Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on antibody treatment for the prevention of migraine headache, closed a $18M Series A financing. Participants include Atlas Venture and OrbiMed.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Provenance Biopharmaceuticals (Waltham, MA) a clinical-stage biopharmaceutical company focused on monoclonal antibody therapy for non-Hodgkins lymphoma and other hematological cancers, closed a $8M Series A financing. Participants include Alopexx Enterprises.

« Previous Entries  Next Page »

to top of page...